Mellor has a particular interest in developing a range of aseptic isolators. He will join David Jackson, director and general manager of the pharmaceutical division.
The two men will work closely together to increase global business by taking Howorth’s pharmaceutical products to new markets, as well as consolidating the company’s success with its existing client base.
Howorth said 2010 was a successful year for the pharmaceutical division, which completed several projects for companies including GlaxoSmithKline, Eisai, sanofi-aventis, Teva and Almirall.
In 2011, the firm will appoint agents in the Far East as part of its global expansion.